OTCMKTS:PBSV Pharma-Bio Serv (PBSV) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free PBSV Stock Alerts $0.73 +0.08 (+12.29%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$0.73▼$0.7350-Day Range$0.65▼$0.9052-Week Range$0.65▼$1.10Volume240 shsAverage Volume2,183 shsMarket Capitalization$16.79 millionP/E Ratio24.37Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Pharma-Bio Serv alerts: Email Address Pharma-Bio Serv MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth37.50%From $0.08 to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pharma-Bio Serv.Read more about Pharma-Bio Serv's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of Pharma-Bio Serv have been sold short.Short Interest Ratio / Days to CoverPharma-Bio Serv has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.8 Dividend Strength Dividend YieldPharma-Bio Serv does not currently pay a dividend.Dividend GrowthPharma-Bio Serv does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Pharma-Bio Serv is 250.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Pharma-Bio Serv will have a dividend payout ratio of 68.18% next year. This indicates that Pharma-Bio Serv will be able to sustain or increase its dividend.Read more about Pharma-Bio Serv's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBSV. Previous Next 1.8 News and Social Media Coverage News SentimentPharma-Bio Serv has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pharma-Bio Serv this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharma-Bio Serv insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Pharma-Bio Serv is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharma-Bio Serv's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Pharma-Bio Serv are expected to grow by 37.50% in the coming year, from $0.08 to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharma-Bio Serv is 24.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharma-Bio Serv is 24.37, which means that it is trading at a less expensive P/E ratio than the Business Services sector average P/E ratio of about 32.45.Price to Book Value per Share RatioPharma-Bio Serv has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pharma-Bio Serv's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Pharma-Bio Serv Stock (OTCMKTS:PBSV)Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.Read More PBSV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBSV Stock News HeadlinesMay 15 at 6:48 AM | americanbankingnews.comPharma-Bio Serv (OTCMKTS:PBSV) Stock Passes Below 200-Day Moving Average of $0.90May 14 at 10:20 AM | msn.comKörber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive RankingMay 2, 2024 | markets.businessinsider.comBBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | markets.businessinsider.comDeep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)April 25, 2024 | markets.businessinsider.comEQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché LaboratóriosApril 23, 2024 | markets.businessinsider.comBiomarin Pharmaceutical earnings preview: what Wall Street is expectingApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market ExpectationsApril 9, 2024 | tmcnet.comSanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment ProgramApril 3, 2024 | benzinga.comLooking Into Biomarin Pharmaceutical's Recent Short InterestMarch 19, 2024 | finance.yahoo.comPBSV Releases Quarterly ResultsMarch 19, 2024 | seekingalpha.comPharma-Bio Serv reports Q1 resultsMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial OutlookMarch 4, 2024 | markets.businessinsider.comMaintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market UncertaintiesFebruary 26, 2024 | marketwatch.comBioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- UpdateFebruary 23, 2024 | markets.businessinsider.comStrong Voxzogo Performance Underpins Buy Rating for BioMarin PharmaceuticalJanuary 30, 2024 | finance.yahoo.comPBSV Expands Margins and MarketsJanuary 28, 2024 | msn.comJubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger DealJanuary 9, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth DriversJanuary 8, 2024 | seekingalpha.comBridgeBio Pharma's Robust Pipeline Could Benefit From A PartnerJanuary 3, 2024 | finance.yahoo.comPBSV Reward Shareholders with High YieldDecember 21, 2023 | finanznachrichten.dePharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special DividendDecember 8, 2023 | msn.comAbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?November 28, 2023 | markets.businessinsider.comBioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In GermanyNovember 7, 2023 | markets.businessinsider.comPromising Future for BridgeBio Pharma: Lebovitz’s Buy Rating Backed by Potential Blockbusters and Pipeline AssetsNovember 6, 2023 | markets.businessinsider.comBridgeBio Pharma Receives Buy Rating Amid Promising Drug Pipeline Developments and Strong Financial PositionSee More Headlines Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/17/2024Next Earnings (Estimated)6/12/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Management consulting services Sub-IndustryN/A Current SymbolOTCMKTS:PBSV CUSIPN/A CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio24.37 Forward P/E Ratio9.14 P/E GrowthN/ANet Income$1.31 million Net Margins4.05% Pretax Margin5.65% Return on Equity3.95% Return on Assets3.10% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio5.10 Sales & Book Value Annual Sales$16.98 million Price / Sales0.99 Cash Flow$0.07 per share Price / Cash Flow9.93 Book Value$0.70 per share Price / Book1.04Miscellaneous Outstanding Shares22,963,000Free Float20,162,000Market Cap$16.79 million OptionableNot Optionable Beta0.55 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Victor Sanchez (Age 53)CEO, President & President of European Operations Comp: $323.67kMr. Pedro J. Lasanta (Age 64)CFO, VP of Finance & Administration and Secretary Comp: $225.6kMs. Elizabeth Plaza (Age 60)Founder & Senior Strategic Consultant Comp: $69.92kMs. Miriam Marrero M.B.A.Human Resources ManagerKey CompetitorsCastellumNYSEAMERICAN:CTMGopher ProtocolOTCMKTS:GOPHATIFNASDAQ:ATIFRyvylNASDAQ:RVYLAeries TechnologyNASDAQ:AERTView All Competitors PBSV Stock Analysis - Frequently Asked Questions How have PBSV shares performed in 2024? Pharma-Bio Serv's stock was trading at $1.05 on January 1st, 2024. Since then, PBSV shares have decreased by 30.4% and is now trading at $0.7310. View the best growth stocks for 2024 here. When is Pharma-Bio Serv's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our PBSV earnings forecast. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) announced its quarterly earnings data on Monday, March, 18th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $2.38 million for the quarter, compared to analysts' expectations of $5 million. Pharma-Bio Serv had a trailing twelve-month return on equity of 3.95% and a net margin of 4.05%. How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv? Pharma-Bio Serv announced a dividend on Thursday, December 21st. Shareholders of record on Tuesday, January 30th will be paid a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date of this dividend is Monday, January 29th. Read our dividend analysis for PBSV. Is Pharma-Bio Serv a good dividend stock? Pharma-Bio Serv (OTCMKTS:PBSV) pays an annual dividend of $0.08 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 250.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, PBSV will have a dividend payout ratio of 68.18% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for PBSV. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE). How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PBSV) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold348 million Americans lives to END as we know it?The Oxford ClubDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
